Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Jul;6(4):e230149.
doi: 10.1148/rycan.230149.

AI-enhanced Mammography With Digital Breast Tomosynthesis for Breast Cancer Detection: Clinical Value and Comparison With Human Performance

Affiliations
Comparative Study

AI-enhanced Mammography With Digital Breast Tomosynthesis for Breast Cancer Detection: Clinical Value and Comparison With Human Performance

Daphne Resch et al. Radiol Imaging Cancer. 2024 Jul.

Abstract

Purpose To compare two deep learning-based commercially available artificial intelligence (AI) systems for mammography with digital breast tomosynthesis (DBT) and benchmark them against the performance of radiologists. Materials and Methods This retrospective study included consecutive asymptomatic patients who underwent mammography with DBT (2019-2020). Two AI systems (Transpara 1.7.0 and ProFound AI 3.0) were used to evaluate the DBT examinations. The systems were compared using receiver operating characteristic (ROC) analysis to calculate the area under the ROC curve (AUC) for detecting malignancy overall and within subgroups based on mammographic breast density. Breast Imaging Reporting and Data System results obtained from standard-of-care human double-reading were compared against AI results with use of the DeLong test. Results Of 419 female patients (median age, 60 years [IQR, 52-70 years]) included, 58 had histologically proven breast cancer. The AUC was 0.86 (95% CI: 0.85, 0.91), 0.93 (95% CI: 0.90, 0.95), and 0.98 (95% CI: 0.96, 0.99) for Transpara, ProFound AI, and human double-reading, respectively. For Transpara, a rule-out criterion of score 7 or lower yielded 100% (95% CI: 94.2, 100.0) sensitivity and 60.9% (95% CI: 55.7, 66.0) specificity. The rule-in criterion of higher than score 9 yielded 96.6% sensitivity (95% CI: 88.1, 99.6) and 78.1% specificity (95% CI: 73.8, 82.5). For ProFound AI, a rule-out criterion of lower than score 51 yielded 100% sensitivity (95% CI: 93.8, 100) and 67.0% specificity (95% CI: 62.2, 72.1). The rule-in criterion of higher than score 69 yielded 93.1% (95% CI: 83.3, 98.1) sensitivity and 82.0% (95% CI: 77.9, 86.1) specificity. Conclusion Both AI systems showed high performance in breast cancer detection but lower performance compared with human double-reading. Keywords: Mammography, Breast, Oncology, Artificial Intelligence, Deep Learning, Digital Breast Tomosynthesis © RSNA, 2024.

Keywords: Artificial Intelligence; Breast; Deep Learning; Digital Breast Tomosynthesis; Mammography; Oncology.

PubMed Disclaimer

Conflict of interest statement

Disclosures of conflicts of interest: D.R. No relevant relationships. R.L.G. No relevant relationships. J.T. Consulting fees from ScreenPoint Medical. F.S. No relevant relationships. J.H. No relevant relationships. A.R. No relevant relationships. K.P. Grants from the Research and Innovation Framework Programme, H2020 FETOPEN, Jubiläumsfonds of the Austrian National Bank, The Vienna Science and Technology Fund, Breast Cancer Research Foundation, and National Institutes of Health; recipient of the MSKCC 2020 Molecularly Targeted Intra-Operative Imaging Award; institution has financial interests in Grail; consulting fees from or relationship with Genentech, Merantix Healthcare, AURA Health Technologies, Guerbet, and NeoDynamics; payment for lectures from the European Society of Breast Imaging, Bayer, Siemens Healthineers, IDKD, Olea Medical, and Roche; support for travel or attending meeting from the European Society of Breast Imaging.

Figures

None
Graphical abstract
Flow diagram depicts patient inclusion. AI = artificial intelligence,
BI-RADS = Breast Imaging Reporting and Data System, DBT = digital breast
tomosynthesis.
Figure 1:
Flow diagram depicts patient inclusion. AI = artificial intelligence, BI-RADS = Breast Imaging Reporting and Data System, DBT = digital breast tomosynthesis.
Scatterplot denotes malignancy scores from ProFound AI (PFAI) and
Transpara systems. For the Transpara system, three score categories
correspond to the level of cancer risk: scores 1–7, 8–9, and
10 correspond to low, intermediate, and elevated risk, respectively
(x-axis). ProFound AI scores are divided into three categories representing
different levels of cancer prevalence, from lowest to highest: 0–29,
30–69, and 70–100 (y-axis).
Figure 2:
Scatterplot denotes malignancy scores from ProFound AI (PFAI) and Transpara systems. For the Transpara system, three score categories correspond to the level of cancer risk: scores 1–7, 8–9, and 10 correspond to low, intermediate, and elevated risk, respectively (x-axis). ProFound AI scores are divided into three categories representing different levels of cancer prevalence, from lowest to highest: 0–29, 30–69, and 70–100 (y-axis).
Comparison of the receiver operating characteristic curves for
ProFound AI (PFAI), Transpara, and human double-reading. The solid red line
represents the reference line.
Figure 3:
Comparison of the receiver operating characteristic curves for ProFound AI (PFAI), Transpara, and human double-reading. The solid red line represents the reference line.

Comment in

Similar articles

Cited by

References

    1. Ferlay J , Colombet M , Soerjomataram I , et al. . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods . Int J Cancer 2019. ; 144 ( 8 ): 1941 – 1953 . - PubMed
    1. Siegel RL , Miller KD , Wagle NS , Jemal A . Cancer statistics, 2023 . CA Cancer J Clin 2023. ; 73 ( 1 ): 17 – 48 . - PubMed
    1. Hickman SE , Baxter GC , Gilbert FJ . Adoption of artificial intelligence in breast imaging: evaluation, ethical constraints and limitations . Br J Cancer 2021. ; 125 ( 1 ): 15 – 22 . - PMC - PubMed
    1. Baker JA , Rosen EL , Lo JY , Gimenez EI , Walsh R , Soo MS . Computer-aided detection (CAD) in screening mammography: sensitivity of commercial CAD systems for detecting architectural distortion . AJR Am J Roentgenol 2003. ; 181 ( 4 ): 1083 – 1088 . - PubMed
    1. Baker JA , Lo JY , Delong DM , Floyd CE . Computer-aided detection in screening mammography: variability in cues . Radiology 2004. ; 233 ( 2 ): 411 – 417 . - PubMed

Publication types

LinkOut - more resources